Λογότυπο www.galinos.gr Beta
 

Ιατροφαρμακευτική πληροφόρηση για τον επαγγελματία υγείας

Φάρμακα Δραστικές ουσίες Συμπληρώματα διατροφής Έλεγχος συγχορήγησης Νόσοι ICD-10
Κλαύδιος Γαληνός
Είσοδος χρηστών
Όνομα χρήστη
Συνθηματικό
Εικονίδιο Είσοδος χρήστη
Εικονίδιο Δωρεάν εγγραφή
Εικονίδιο Ανανέωση συνθηματικού

Ακολουθήστε μας Λογότυπο Facebook Λογότυπο Twitter

Αναζήτηση σε 63811 καταχωρήσεις
Εικονίδιο αναζήτησης

Βιβλιογραφική αναφορά

Προτάσεις

SPC, UK: Wellvone 750mg/5ml oral suspension (2010)

Εκδότης

Εκδότης GlaxoSmithKline UK
Διεύθυνση Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Σφάλμα Για την προβολή της πλήρους καταχώρησης χρειάζεται να έχετε συνδρομή σε ισχύ (αγορά συνδρομής).
Ολοκληρώνοντας τη διαδικασία δωρεάν εγγραφής θα αποκτήσετε, χωρίς καμία δέσμευση εκ μέρους σας, συνδρομή διάρκειας 30 ημερών.

Περιεχόμενα

Name of the medicinal product

Wellvone 750 mg/5 ml oral suspension.

Qualitative and quantitative composition

Each ml of suspension contains 150 mg atovaquone A unit dose of 5 ml contains 750 mg atovaquone. For ...

Pharmaceutical form

Oral suspension. Wellvone oral suspension is a bright yellow liquid.

Therapeutic indications

Wellvone Suspension is indicated for: Acute treatment of mild to moderate Pneumocystis pneumonia (PCP, ...

Posology and method of administration

The importance of taking the full prescribed dose of Wellvone with food should be stressed to patients. ...

Contraindications

Wellvone Suspension is contra-indicated in individuals with known hypersensitivity to atovaquone or to ...

Special warnings and precautions for use

Diarrhoea at the start of treatment has been shown to be associated with significantly lower atovaquone ...

Interaction with other medicinal products and other forms of interaction

As experience is limited, care should be taken when combining other drugs with Wellvone. Concomitant ...

Pregnancy and lactation

There is no information on the effects of atovaquone administration during human pregnancy. Atovaquone ...

Effects on ability to drive and use machines

There have been no studies to investigate the effect of Wellvone on driving performance or the ability ...

Undesirable effects

Patients participating in clinical trials with atovaquone have often experienced undesirable effects ...

Overdose

There is insufficient experience to predict the consequences or suggest specific management of atovaquone ...

Pharmacodynamic properties

Pharmacotherapeutic group: Antiprotozoals ATC Code: P01AX06 Mode of Action Atovaquone is a selective ...

Pharmacokinetic properties

Atovaquone is a highly lipophilic compound with a low aqueous solubility. It is 99.9% bound to plasma ...

Preclinical safety data

Carcinogenicity Oncogenicity studies in mice showed an increased incidence of hepatocellular adenomas ...

List of excipients

Benzyl alcohol Xanthan Gum Poloxamer 188 Saccharin Sodium Purified water Tutti Frutti Flavour (Firmenich ...

Incompatibilities

Not applicable.

Shelf life

2 years, After first opening, the suspension may be stored for up to 21 days.

Special precautions for storage

Do not store above 25°C. Do not freeze.

Nature and contents of container

A 240 ml high density polyethylene bottle with child resistant polypropylene closure, containing 226 ...

Special precautions for disposal and other handling

Do not dilute.

Marketing authorization holder

Glaxo Wellcome UK Ltd trading as GlaxoSmithKline UK Stockley Park West Uxbridge, Middlesex UB11 1BT ...

Marketing authorization number(s)

PL 10949/0271

Date of first authorization / renewal of the authorization

Date of first authorisation: 25 March 1997 Date of last renewal: 21 May 2006

Date of revision of the text

15 April 2010
Απαγορεύεται η αναπαραγωγή και αναδιανομή. Το έργο επεξεργασίας των παραπάνω πληροφοριών αποτελεί πνευματική ιδιοκτησία της Ergobyte Πληροφορική Α.Ε. και προστατεύεται από τη νομοθεσία περί πνευματικών δικαιωμάτων.